I. COMMENCED TRADING IN JULY
Company (Symbol) |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out(M) |
Lead, Other Underwriters |
Gross ($M) |
Net ($M) |
INITIAL OFFERINGS | ||||||||
BioMarin Pharmaceutical Inc. (BMRN) |
5/4 |
7/22 |
4.5S |
$13 |
34.1 |
U.S. Bancorp Piper Jaffray; Vontobel Securities Ltd.; Schroders Securities Co. Ltd.; Leerink Swann & Co. | $58.5 |
$54.4E |
Biopure Corp. (BPUR) |
5/19 |
7/30 |
3.5S |
$12 |
22.1 |
J.P. Morgan & Co.; Adams, Harkness & Hill Inc.; Robert W. Baird & Co. |
$42 |
$37.9E |
Genentech Inc. (NYSE:DNA) |
7/20 |
7/20 |
20S |
$97 |
127.3 |
J.P. Morgan & Co.; Goldman, Sachs & Co.; Merrill Lynch & Co.; Warburg Dillon Read LLC; BancBoston Robertson Stephens | $1,940 |
** |
FOLLOW-ON OFFERINGS | ||||||||
Alizyme plc (LSE:AZM) | 6/28 | 7/5 |
1.6U |
74p (US $1.19) |
N/A |
N/A | £5.2 (US $8.4)* | £4.9E (US $7.9E) |
Angiotech Pharmaceuticals Inc. (TSE:ANP) |
6/17 |
7/9 |
1.4S |
$11.50 | N/A |
Levesque Beaubien Geoffrion Inc. and Loewen, Ondaatje, Mccutcheon Ltd. | C $16.3 (US $10.9)* |
C $15.5E (US $10.4E) |
Ribozyme Pharmaceuticals Inc. (RZYM) |
3/26 |
7/7 |
1.8S | $3.50 |
11 |
Hambrecht & Quist LLC (Placement agent) |
$6.3 |
$5.8 |
** Roche Holdings Inc., Genentech's major stockholder, is offering all the shares of common stock in this transaction and will receive the proceeds of the offering. | ||||||||
II. FILED AND PENDING
Company (Symbol) |
Date Filed |
Shares/Units (M) |
Price Range | Shares Out (M) |
Lead, Other UWs |
Value (M) |
INITIAL OFFERINGS | ||||||
There were no initial public offerings filed in July. | ||||||
FOLLOW-ON OFFERINGS | ||||||
Advanced Tissue Sciences Inc. (ATIS) |
7/12 |
5 |
$3.25 |
47.5 |
Shares directly offered by the company | $16.25 |
Aquila Biopharmaceuticals Inc.(AQLA) | 6/4 |
0.75 |
$2 |
6.9 |
|
$1.5 |
NeoTherapeutics Inc.(NEOT) |
6/18 |
3.5 |
$13 |
10.2 |
Joseph Charles & Associates |
$45.5 |
Shaman Pharmaceuticals Inc.(OTC BB:SHMN) |
5/7 |
1 |
$15 |
3.2 |
N/A |
$15 |
Vion Pharmaceuticals Inc.(VION) |
7/27 |
3.6 |
5.38 |
19.2 |
Brean Murray & Co. Inc. |
$19.4 |
* Canadian dollars converted to U.S. dollars at a rate of C$1.00=U.S.$0.67. | ||||||
* British pounds converted to U.S. dollars at a rate of GBP£1.00=U.S.$1.62. | ||||||
1 Aquila registered 750,000 shares to be sold in a direct limited placement to be negotiated by the company. | ||||||